Janux TherapeuticsJANX
JANX
About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Employees: 91
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
295% more call options, than puts
Call options by funds: $17.2M | Put options by funds: $4.35M
118% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 44
1.51% more ownership
Funds ownership: 110.96% [Q4 2024] → 112.47% (+1.51%) [Q1 2025]
15% less funds holding
Funds holding: 214 [Q4 2024] → 181 (-33) [Q1 2025]
30% less funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 7 (-3) [Q1 2025]
47% less capital invested
Capital invested by funds: $3.43B [Q4 2024] → $1.81B (-$1.63B) [Q1 2025]
62% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 52
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$65
169%
upside
Avg. target
$65
169%
upside
High target
$65
169%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Raymond James Sean McCutcheon | 169%upside $65 | Outperform Initiated | 11 Jul 2025 |
Financial journalist opinion
Neutral
Business Wire
5 days ago
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, will host its virtual R&D Day today at 1:30 PM PT. The event will highlight the company's continued momentum in advancing its novel imm.
Neutral
Business Wire
1 week ago
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual R&D Day on July 24, 2025.
Neutral
Business Wire
2 months ago
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Janeen Doyle, MBA, as Chief Corporate and Business Development Officer. “Janeen's unique blend of corporate development, strategic execution, and cli.
Neutral
Business Wire
2 months ago
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. “We are proud to advance into the next phase of our clinical journey for JA.
Neutral
Business Wire
2 months ago
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates.
Positive
Seeking Alpha
3 months ago
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout
Janux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position, with $1.03 billion in cash, reduces near-term dilution risk and supports pipeline advancement without immediate capital needs. The recent stock pullback presents a buying opportunity, driven by profit-taking and broader market weakness, not negative company updates.
Neutral
24/7 Wall Street
4 months ago
Insiders Are Loading Up on These 4 Biotech Stocks Now
Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so.
Neutral
Business Wire
5 months ago
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “2024 was an exceptional year for Janux as we displayed t.
Neutral
Business Wire
6 months ago
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer.
Positive
Seeking Alpha
6 months ago
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRACTr and TRACIr platforms differentiate it in immunotherapy by enabling tumor-activated bispecific therapeutics for precise cancer targeting with minimal systemic toxicity. JANX's robust balance sheet, with $658.1 million in liquid assets and no debt. Oppenheimer identified Janux as a top biotech buyout candidate for 2025, citing its innovative platform and promising.
Charts implemented using Lightweight Charts™